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In the last decade several groups have determined the key role of hemichannels formed
by pannexins or connexins, extracellular ATP and purinergic receptors in physiological and
pathological conditions. Our work and the work of others, indicate that the opening of
Pannexin-1 hemichannels and activation of purinergic receptors by extracellular ATP is
essential for HIV infection, cellular migration, inflammation, atherosclerosis, stroke, and
apoptosis. Thus, this review discusses the importance of purinergic receptors, Panx-1
hemichannels and extracellular ATP in the pathogenesis of several human diseases and
their potential use to design novel therapeutic approaches.
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INTRODUCTION
In recent years it has become evident that pannexin (Panx)-1
hemichannels in concert with extracellular adenosine triphos-
phate (ATP) and purinergic receptors are involved in several phys-
iological and pathological conditions. Recent evidence suggests
the participation of Panx-1 hemichannels, extracellular ATP and
purinergic receptors in the coordination of events such as cellu-
lar activation, apoptosis, stress signals, secretion of inflammatory
cytokines, and HIV replication have been explored (Pelegrin,
2008; Schenk et al., 2008; Chekeni et al., 2010; Woehrle et al.,
2010; Qu et al., 2011; Seror et al., 2011; Orellana et al., 2013). This
review will describe these interactions in the context of several
human diseases.
The Panx family consists of three members, Panx-1, -2, and -3
(Baranova et al., 2004). Panx-1 is ubiquitously expressed (Scemes
et al., 2009). Panx-2 is mainly expressed in the central nervous
system (CNS), while Panx-3 is localized in osteoblasts, synovial
fibroblasts and chondrocytes (Barbe et al., 2006; Ray et al., 2006).
Originally, it was speculated that Panx hemichannels could form
gap junction channels between adjacent cells (Bruzzone et al.,
2003, 2005; Bruzzone and Dermietzel, 2006). However, current
evidence suggests that Panxs cannot form intercellular channels
(Boassa et al., 2007). Asparagine residues found on the extracellu-
lar domains of Panx are glycosylated and therefore make docking
between two Panxs highly unlikely (Boassa et al., 2007; Penuela
et al., 2007).
Panxs are structurally similar to connexins (Cxs), although
they share no sequence homology. Panx consist of a cytoso-
lic N-terminal domain, four transmembrane domains with two
extracellular loops and a cytosolic C-terminal domain (Boassa
et al., 2007; Penuela et al., 2007). Panxs form large pore chan-
nels located on the plasma membrane, which are known to
open during membrane depolarization, by changes in intracel-
lular Ca2+ signaling, vasodilation, vasoconstriction, taste sensa-
tion, airway defense, learning/memory, cellular differentiation,
cell death and during innate, and adaptive immune responses
(Chekeni et al., 2010; MacVicar and Thompson, 2010; Prochnow
et al., 2012). Upon opening of these hemichannels small signal-
ing molecules such as ATP are released to the extracellular space,
which then signal through surface receptors including purinergic
receptors.
Purinergic receptors are divided into two groups, Adenosine
receptors (ARs) for adenosine and P2 receptors for ATP/ADP
receptors (Fredholm et al., 1994; Ralevic and Burnstock, 1998). P2
receptors are subdivided into ionotropic P2X and metabotropic
P2Y receptors. P2X receptors are ligand gated ion channels that
form trimeric structures using individual subunits (P2X1, P2X2,
P2X3, P2X4, P2X5, P2X6, and P2X7) (Fredholm et al., 1994;
Ralevic and Burnstock, 1998). P2Y receptors are G-protein cou-
pled receptors with eight subtypes (P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11, P2Y12, P2Y13, P2Y14). Purinergic receptor signaling is
fundamental in many cellular processes such as platelet aggre-
gation, exocrine and endocrine secretion, endothelial-mediated
vasodilation, nociceptive mechanosensory transduction, neuro-
modulation, neuroprotection, cell proliferation, differentiation,
migration, embryological development, wound healing, inflam-
mation, and cytokine secretion (Abbracchio and Burnstock, 1998;
Burnstock and Knight, 2004; Burnstock and Verkhratsky, 2010;
Burnstock, 2012). Upon release of ATP into the extracellu-
lar space, several enzymes degrade ATP into ADP, AMP and
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adenosine, which also signals through purinergic receptors and
adenosine receptors.
ARs (A1, A2A, A2B, and A3) were initially classified as P1
receptors until it was discovered that their agonist was adeno-
sine (Fredholm et al., 1994; Junger, 2011). As indicated above,
the production of extracellular adenosine is achieved by hydrolyz-
ing ATP in a stepwise manner by ectonucleotidases (Yegutkin,
2008). These enzymes include the Ecto-nucleotide pyrophos-
phatase/phosphodiesterase (E-NPP) family comprised of three
enzyme subtypes, which hydrolyses ATP to AMP, and Ecto-
nucleoside triphosphate diphosphydrolase (E-NTDPase) family
comprised of eight enzyme subtypes, which can hydrolyze ATP to
ADP or AMP. Finally, Ecto-5’-nucleotidase/ CD73 in tandemwith
CD38 can hydrolyze AMP to adenosine, which then activates the
ARs (Yegutkin, 2008; Junger, 2011). In Figure 1 we summarized
the interaction between Panx-1 hemichannels, purinergic recep-
tors, adenosine receptor, as well as the extracellular metabolism of
ATP (Figure 1). In the next sections we will discuss the involve-
ment of this complex in several human diseases.
PURINERGIC RECEPTORS, PANX-1 HEMICHANNELS AND
THEIR INVOLVEMENT IN ISCHEMIC STROKE
According to the World Health Organization (WHO), 15 million
people suffer stroke worldwide each year, resulting in 5 million
deaths and another 5 million survivors that are permanently
disabled (www.WHO.int). Ischemic stroke results from a perma-
nent or transient decrease in cerebral blood flow. This decrease
in blood flow is usually caused by the obstruction of a cerebral
artery by an embolus or local thrombosis (Katsura et al., 1994;
Martin et al., 1994; Dirnagl et al., 1999). Brain tissue requires a
high intake of glucose and oxygenation for proper cerebral func-
tion. The restriction of cerebral blood flow impairs the delivery of
glucose and oxygen and consequently leads to tissue damage by
mechanisms dependent on excitotoxicity, peri-infarct depolariza-
tions, inflammation and programmed cell death (Katsura et al.,
1994; Martin et al., 1994; Dirnagl et al., 1999).
Thompson et al. demonstrated a connection between
Panx-1 hemichannels and ischemia using acutely isolated hip-
pocampal neurons in which oxygen and glucose deprivation
(OGD) resulted in opening of Panx-1 hemichannels (Thompson
et al., 2006). BlockingNMDA (N-methyl-D-aspartate), AMPA (2-
amino-3-[5-methyl-3-oxo-1,2-oxazol-4-yl] propanoic acid) and
P2X7 receptors failed to modify the large anoxic depolarization
activated by OGD, which corresponded to opening of Panx-
1 hemichannels. Therefore, the mechanism by which Panx-1
hemichannels are opened during OGD was thought to be inde-
pendent from ligand-gated receptors (Thompson et al., 2006).
Recent evidence suggests that anoxia induces NMDA receptor
FIGURE 1 | A schematic representation of the elements involved in
the release of ATP by opening of Panx-1 hemichannels and
subsequent activation of purinergic signaling. Pathological or
physiological stimuli result in the opening of Panx-1 hemichannels
promoting the release of ATP from the cell. ATP/ADP/AMP could then
bind to P2X and P2Y receptors. Ecto-nucleoside triphosphate
diphosphydrolase (E-NTDPase) including ecto-ATPase and ATP-diphospho-
hydrolase promotes the hydrolysis of ATP to ADP or from ADP to AMP
(2). Ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) hydrolysis
ATP to AMP (1). AMP is further hydrolyzed by Ecto-5’-nucleotidase/ CD73
(3) which promotes the formation of adenosine. Adenosine then activates
adenosine receptors (AR).
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activation, which activates Src kinases, that participates in the
opening of Panx-1 hemichannels (Weilinger et al., 2012). This
suggests a signaling pathway involving the coupling of NMDA
receptors using Src Kinases to Panx-1 hemichannels. Furthermore
overstimulation of NMDA receptors activates the opening of
Panx-1 hemichannels in neurons (Thompson et al., 2008).
However, another study demonstrated that inhibiting gluta-
mate receptors of hippocampal pyramidal slices prevented anoxic
depolarization and that Panx1 hemichannels did not generate
a large inward current associated with anoxic depolarization
(Madry et al., 2010). Therefore, future studies are required to
clarify the participation of Panx-1 hemichannels in response to
anoxia/ischemia.
ATP is a neurotransmitter that mediates communication
between CNS cells, including astrocytes and neurons. Initially, it
was believed that the mechanism by which ATP was released from
astrocytes involved Connexin43 (Cx43) hemichannels. However,
experiments conducted using wild type, Cx43 null, and Panx-
1 knocked down astrocytes provided evidence indicating that
downregulation of Panx-1 prevented the release of ATP from
astrocytes (Iglesias et al., 2009). Downregulation of Cx43 has
no affect on the release of ATP from astrocytes. In contrast,
experiments using conditional Cx43 knockout demonstrated that
ATP release and recruitment of microglia/macrophages follow-
ing injury was reduced and the recovery of the animals was
improved, suggesting a role for Cx43 hemichannels in inflam-
mation but also in recovery (Huang et al., 2012). Orellana
et al. demonstrated that under hypoxic conditions astrocytes
release ATP and glutamate activating neuronal Panx-1 hemichan-
nels via P2X and NMDA receptors resulting in neuronal death
(Orellana et al., 2011). This study demonstrates that neurons
could be protected from ischemia-associated damage by blocking
NMDA/P2X receptors as well as Panx-1 hemichannels (Orellana
et al., 2011).
Furthermore experiments conducted in the double Panx-1 and
Panx-2 knockout mice subjected to permanent right middle cere-
bral artery occlusion (MCAO) demonstrated that Panx channels
contributed to ischemic brain injury in vivo (Bargiotas et al.,
2011). The double knockout mice subjected to MCAO demon-
strated improved neurological deficit, reduced movement latency
and infarct size as compared to the wild type (Bargiotas et al.,
2011). Single knockouts of either Panx-1 or Panx-2 did not differ
in ischemic brain injury from wild type; however, Panx-2 knock-
out mice were partially protected from ischemic injury. These
data suggests that Panx-1 and Panx-2 work together to regulate
response to injury.
Ischemia induces astrocytes to release ATP, which rapidly acti-
vates microglia resulting in the formation of a barrier between the
healthy and injured tissue in order to promote repair (Davalos
et al., 2005; Nimmerjahn et al., 2005). Moreover, an excess
release of nucleotides can result in accelerated neurodegenera-
tion (Di Virgilio et al., 2009). An excessive level of extracellular
ATP in oligodendrocytes induces a rise in cytosolic Ca2+ by acti-
vating P2 receptors and P2Y7 receptors (Kirischuk et al., 1995;
James and Butt, 2001). Using primary cultures of oligodendro-
cytes it was demonstrated that OGD induced the release of ATP
and blocking of P2X7 receptors using periodate oxidized ATP
(oATP) or Brilliant Blue G (BBG) reduces the ischemic-induced
ionic imbalance. In addition, reduction in opening of Panx
hemichannels using blockers such as mefloquine and flufenamic
acid reduced extracellular ATP levels after OGD attenuating
ischemic damage. These data indicates that OGD opens Panx
hemichannels inducing the release of ATP which then activates
P2X7 receptors causing oligodendrocytes failure, myelin damage
and axon dysfunction (Domercq et al., 2010).
Furthermore, elevations in the expression of several P2 recep-
tors (P2X1, P2X2, P2X4, P2X7, and P2Y4) during ischemia have
been demonstrated suggesting increased sensitivity of neurons to
extracellular concentration of ATP (Cavaliere et al., 2002, 2003,
2007). Using spontaneously hypertensive rats (SHR) subjected
to MCAO Lammer et al. demonstrated that inhibition of P2
receptors by pyridoxalphosphate-6-azophenyl-2’, 4’-disulfonate
(PPADS) improved the recovery of the cortical electrophysiolog-
ical and motor functions (Lammer et al., 2006, 2011). PPADS
does not pass through the blood brain barrier; therefore, the
rats were infused by intracerebroventricular administration for 7
days after MCAO. Furthermore, analysis of motor coordination
demonstrated that blockade of P2 receptors by PPADS resulted
in improved motor recovery when compared to non-PPADS
treated rats subjected to MCAO (Lammer et al., 2011). Thus,
opening of Panx-1 hemichannels and activation of P2 receptors
play a major role in the pathogenesis of ischemia and blocking
or knocking down these hemichannels/receptors could provide
additional therapeutic interventions to reduce damage and to
improve recovery in response to ischemic events.
PANX HEMICHANNELS, PURINERGIC RECEPTORS AND
INFLAMMATION
Tissue damage causes the release of ATP from injured cells, result-
ing in P2 receptor mediated purinergic signaling and the initia-
tion of inflammation (Bours et al., 2006; Kanneganti et al., 2006;
Mariathasan et al., 2006). During this process in both immune
and parenchymal cells, hemichannels are open in concert with
activation of purinergic receptors to control cellular migration,
inflammation, and damage.
As indicated above an essential aspect of inflammation is the
migration of inflammatory cells into areas of injury. Cellular
migration requires mechanisms to allow orientated movement
including sensing changes in the chemoattractant gradient, acti-
vation of G-protein coupled receptors, and downstream signaling
resulting in cytoskeletal rearrangement leading to movement
toward the chemotactic signal. Recent evidence suggests that
Panx-1 hemichannels and P2X7 could initiate an intracellular
signaling cascade which, results in rearrangement of the F-actin
microfilament network in C6 glioma cells causing the assembly
of large tumor cell aggregates (Bao et al., 2012). A similar actin
microfilament rearrangement asmentioned above is a critical step
in cellular migration. Intracellular ATP is released through Panx-1
hemichannels and then binds to the P2X7 receptor (see Figure 1),
which causes an increase in intracellular calcium resulting in actin
microfilament organization (Cotrina et al., 1998; Suadicani et al.,
2006). Current evidence suggests that the release of ATP by a
Panx-1 hemichannel mediated mechanism from apoptotic cells
function as “Find me signals” in order to recruit monocytes to
www.frontiersin.org March 2014 | Volume 5 | Article 96 | 3
Velasquez and Eugenin Hemichannels in human diseases
areas of damage (Chekeni et al., 2010). Our laboratory demon-
strated that chemokines that bind to CCR5 or CXCR4 transiently
open Panx-1 hemichannels in T lymphocytes, suggesting that
these channels also play a key role in surveillance and inflam-
mation. Thus our work and the work of others propose that
Panx-1 hemichannels, extracellular ATP and purinergic receptors
are essential in immune surveillance and inflammation.
Migration in a chemotactic gradient requires excitatory sig-
nals at the front of the cell and inhibitory signals at the back of
the cell (Berzat and Hall, 2010). In this context ATP released by
Panx-1 hemichannels stimulates the P2Y2 receptors, which pro-
vides the excitatory signal at the front of the cell (Chen et al., 2006,
2010). Bao et al. demonstrated that Panx-1 hemichannels pro-
vides the ligand for the adenosine A2A receptors that plays a role
in the inhibitory signal at the back of the cell (Bao et al., 2013).
Resting neutrophils had a uniform distribution across the cell of
A2A receptors and polarized cells had the A2A receptors redis-
tributed to the back of the cell where they provided the inhibitory
signal. Inhibition of Panx-1 hemichannels blocked A2A receptor
stimulation preventing the accumulation of cAMP, impairing the
polarization and migration of neutrophils in a chemotactic gradi-
ent (Bao et al., 2013). These results suggest that chemoattractant
receptors require opening of Panx-1 hemichannels in order to
provide excitatory and inhibitory signals for efficient chemotaxis
of neutrophils.
Inflammasomes are large multiprotein complexes leading to
caspases-1-activated maturation of IL-1β and IL-18. The NLRP3
inflammasome is the most studied inflammasome containing
NLRP3 as a scaffold protein (Schroder and Tschopp, 2010; Davis
et al., 2011). NLRP3 inflammasomes are activated via danger-
associated molecular patterns (DAMPs) such as extracellular ATP,
which act through P2X7 receptors (Lich et al., 2006; Meylan
et al., 2006; Said-Sadier and Ojcius, 2012). There are several
proposedmechanisms, which induce NLRP3 inflammasome acti-
vation such as, reactive oxygen species (ROS) production and
apoptosis (Said-Sadier and Ojcius, 2012). Cell induced ROS pro-
duction and immune activation, have been shown to induce
caspase-1 activation (Cruz et al., 2007; Said-Sadier and Ojcius,
2012). Hung et al. demonstrated that activation of P2X4 and
P2X7 in response to ATP released by Panx-1 hemichannels con-
tributed to ATP induced ROS production and inflammasome
activation in gingival epithelial cells (Hung et al., 2013). Inhibitors
of P2X4, P2X7, and Panx-1 significantly reduced ATP depen-
dent production of ROS. Reduced expression of P2X4, P2X7, and
Panx-1 using siRNA demonstrated that both purinergic recep-
tors and Panx-1 hemichannel were required for ATP-induced ROS
production in primary and immortalized gingival epithelial cells
(Hung et al., 2013). Furthermore, recent evidence identifies that
the NLRP3 inflammasome is activated during the phagocytosis
of dying autophagic cells. This mechanism involves the release of
ATP through Panx-1 hemichannels of the dying autophagic cell,
P2X7 receptor activation and potassium efflux (Ayna et al., 2012).
In agreement, patients who have chronic lung inflammation
such as allergic asthma or chronic obstructive pulmonary disease
have enhanced extracellular ATP levels in the bronchoalveolar
space, as well as in the bronchoalveolar lavage fluids (BALF)
suggesting that the enhanced lung inflammation observed in
these individuals may be associated with ATP dysregulation and
purinergic receptor activation (Idzko et al., 2007; Lommatzsch
et al., 2010). Furthermore, P2X7 receptor deficient mice have
been shown to have less neutrophil airway influx and Panx-
1 hemichannel inhibitors partially prevent further neutrophil
airway influx and cytokine production (Riteau et al., 2010).
Extracellular ATP serves as a danger signal to the immune sys-
tem by binding to P2X7 receptor and activating NALP3 and
caspase-1 which then leads to the maturation and release of IL-
1β, eventually forming the NALP3 inflammasome (Ferrari et al.,
2006; Kanneganti et al., 2006; Mariathasan et al., 2006; Sutterwala
et al., 2006; Di Virgilio, 2007). Extracellular ATP induced caspase-
1 activation and IL-1β maturation requires P2X7 receptor and
Panx-1 hemichannel (Pelegrin and Surprenant, 2006; Locovei
et al., 2007). These data further suggests the involvement of Panx-
1 hemichannels, purinergic receptors and extracellular ATP in
inflammasome activation.
Another human disease involving Panx-1 hemichannels is
inflammatory bowel diseases (IBD) including ulcerative colitis,
and Crohn’s disease. These diseases are chronic conditions asso-
ciated with gut dysfunction resulting from alterations in the
enteric nervous system leading to severe symptoms (Mawe et al.,
2009). Currently not much is known about the expression of
Panx-1 in the intestines. However, one study showed the expres-
sion of innexins in the gut of nematodes, which were needed
for gut motility (Peters et al., 2007). Recently Gulbransen et al.
showed using a mouse model of colitis that Panx-1 hemichan-
nels are required for P2X7 receptor mediated enteric neuron cell
death in intestinal inflammation (Gulbransen et al., 2012). They
identified that Panx-1 hemichannels play a key role in enteric neu-
ronal damage, leading to organ dysfunction. Inhibition of Panx-1
hemichannels protects neurons and maintains proper control of
the colonic muscles preserving motility (Gulbransen et al., 2012).
Diezmos et al. described the expression of Panx-1 in the human
colon; they also described alterations in the expression of Panx-1
in IBD patients (Diezmos et al., 2013). Panx-1 mRNA and protein
was present in all layers of the human colon. There was also dense
expression of Panx-1 on the submucosal and myenteric ganglia
further confirming the involvement of Panx-1 in neural control
of colonic motility (Diezmos et al., 2013). These findings suggest
a critical role of Panx-1 hemichannels in the pathophysiology of
enteric plexus damage during IBD.
As described above ATP release by opening of Panx-1
hemichannels results not only in activation of ATP receptors but
also in degradation of ATP to ADP, AMP, and adenosine. CD39
and CD73 are ectonucleotidases, which degrade ATP, ADP, and
AMP to adenosine (see Figure 1). These ectonucleotidases play an
essential role in maintaining immune homeostasis. Regulatory T
cells (Tregs) are mediators of inflammatory response. High levels
of CD39 and CD73 are expressed on the surface of Foxp3+ Treg
cells (Mandapathil et al., 2009; Schuler et al., 2011). Murine Treg
cells increase CD39 activity after activation of the T cell recep-
tor and non-activated cells had inactive CD39 (Borsellino et al.,
2007). Adenosine derived from the enzymatic breakdown of ATP
by CD39 and CD73 mediates a considerable portion of the anti-
inflammatory activities of Treg cells (Deaglio et al., 2007). Romio
et al. showed that adenosine produced by Treg cells in concert
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with A2A receptors downregulated nuclear factor- κB (NF- κB)
activation in T effector cells, which in turn reduced the release of
proinflammatory cytokines and chemokines (Romio et al., 2011).
Activation of the A2A receptor on Treg cells promotes the expan-
sion of these cells, thereby increasing immune regulation (Ohta
et al., 2012). In humans 90% of Foxp3+ Treg cells also express
CD39 however CD73 expression is minimal (Mandapathil et al.,
2009; Dwyer et al., 2010;Mandapathil et al., 2010). Antonioli et al.
speculated that CD73 may be secreted from human Treg cells and
is responsible for the production of adenosine (Antonioli et al.,
2013). Qiu et al. demonstrated that cells co-expressing Panx-1
hemichannel and P2Y or P2X7 receptors exposed to high levels
of ATP, only transiently activates Panx-1 hemichannel (Qiu and
Dahl, 2009). ATP instead of causing a positive feedback loop is
actually causing a negative feedback loop and inactivating Panx-
1 hemichannel. This mechanism could provide another mode of
immuneregulation suppressing the immune response in order to
prevent damage caused by prolonged inflammation.
PURINERGIC/ADENOSINE RECEPTORS AND THEIR ROLE IN
ATHEROSCLEROSIS
Atherosclerosis is a chronic inflammatory disease affecting the
vessel wall and a major health issue worldwide (Koupenova et al.,
2012a,b). One of the major components of atherosclerosis is the
formation of arterial plaques. The progression of atherosclerosis
begins with the recruitment of inflammatory monocytes to the
area of lipid deposition or arterial injury (Glass and Witztum,
2001; Reiss and Glass, 2006). As discussed in the previous sec-
tion migration is a Panx-1 hemichannel, purinergic receptor and
extracellular ATP dependent process. Infiltrating macrophages in
the arterial wall take up large amounts of oxidized low-density
lipoprotein (ox-LDL) becoming foam cells loaded with choles-
terol (Stary et al., 1994). The accumulation of foam cells leads to
the formation of fatty streaks, increase in arterial wall thickness,
reduction of oxygen diffusion into the tissue and development
of advanced atherosclerosis (Gessi et al., 2010; Hansson and
Hermansson, 2011; Moore and Tabas, 2011; Koupenova et al.,
2012a,b).
Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric tran-
scription factor comprised of α and β subunits (Wang and
Semenza, 1995). HIF-1 adapts cells to low oxygen partial pressure
and induces target genes that influence energy metabolism, cell
proliferation, hematopoiesis, vascular development, and vaso-
tone (Semenza et al., 1994; Liu et al., 1995; Carmeliet et al.,
1998; Kourembanas et al., 1998; Lacombe and Mayeux, 1998;
Rose et al., 2002). Zones of hypoxia occur in the atheroscle-
rotic plaque, a result of impaired oxygen diffusion due to the
thickness of the lesion, as well as high oxygen consumption by
the foam cell. Furthermore, it was demonstrated that ox-LDL
induce HIF-1α accumulation in human Mono-Mac-6 (MM6)
macrophages (Shatrov et al., 2003). Jiang et al. investigated the
gene expression profiles of cultured human U937 cells trans-
fected by HIF-1α-siRNA in response to 24 h of exposure to
ox-LDL. Their results indicated that HIF-1α-siRNA inhibits the
development of macrophage derived foam cells with ox-LDL
by inhibiting the expression of HIF-1α (Jiang et al., 2007). A
key function of HIF-1α is the expression of vascular endothe-
lial growth factor (VEGF). VEGF is a regulator of angiogenesis
during embryogenesis, skeletal growth and reproductive func-
tions (Ferrara et al., 2003). Together HIF-1α and VEGF are
involved in angiogenesis and atherogenesis. As described above
the expression of HIF-1α in macrophages under atherogenic
conditions promotes the formation of foam cells. Foam cells,
macrophages and the U937 myelomonocytic cell line were indi-
vidually cultured and treated with adenosine under hypoxic con-
ditions which resulted in the accumulation of HIF-1α in all the
cells (Gessi et al., 2010). When A1, A2A, A2B, and A3 receptors
were knocked down using siRNA there was a reduction in the
accumulation of HIF-1α in the cells. In addition, the production
of VEGF in foam cells was increased when adenosine was added
and strongly reduced with the addition of A2B, and A3 antagonist
respectively (Gessi et al., 2010). Hypoxia stabilizes HIF-1α, result-
ing in the accumulation of adenosine (Gessi et al., 2010). Notably,
it can be speculated that in this adenosine-mediated atheroscle-
rosis mechanism, Panx-1 hemichannels may play a role in the
release of intracellular ATP into the extracellular environment
leading to the formation of adenosine (Figure 1).
Conversely Koupenova et al. determined that the absence of
A2B adenosine receptor expression in the liver resulted in a worse
atherosclerotic outcome in the double knockout mouse model of
apolipoproteinE (ApoE) and A2B adenosine receptor which were
fed a high fat/high cholesterol diet (Koupenova et al., 2012a,b).
Lack of A2B adenosine receptor led to an elevation of plasma
lipids and plaque formation. In this model the liver is responsi-
ble for contributing to the anti-atherosclerotic phenotype. Under
normal conditions the liver expresses low levels of A2B adenosine
receptor. However, with a high fat diet, levels of A2B receptors
in the liver increase. Activation of A2B receptor in hepatocytes
in vivo and in vitro causes a decrease in the transcription fac-
tor sterol regulatory element binding protein-1 (SREBP-1), which
regulates lipid synthesis. Moreover, eliminating A2B adenosine
receptor in the liver of the mouse model increased the lev-
els of SREBP-1 and its downstream targets acetyl coenzyme-A
carboxylase- α (ACC) and fatty acid synthase (FAS) resulting
in upregulation of lipid synthesis. Resulting in the formation
of foam cells and the development of atherosclerotic plaques.
(Koupenova et al., 2012a,b).
As mentioned above the formation of an atherosclerotic
plaque begins with the uptake and accumulation of cholesterol
by macrophages and is also influenced by endothelial dysregu-
lation. These atherosclerotic plaques are composed of smooth
muscle cells (SMCs), which under normal physiological condi-
tions are found in the medial layer of the artery wall. However,
under atherosclerotic conditions SMCs lose their contractile ele-
ment and gain the ability to replicate and migrate into the
intima of the arterial wall (Gorski and Walsh, 1995). Once in
the intima SMCs proliferate and begin depositing fibrotic con-
nective tissue (Watson et al., 1998). All of these deregulated
cells act as a cover for the fibrous cap that stabilizes the plaque
by covering the lipid rich regions. Adenosine and ATP medi-
ate endothelial cell growth, migration, proliferation and death
(Burnstock, 2006). ATP binding of P2Y2 and/or P2Y4 stimu-
lates SMC cell proliferation via amitogen-activated protein kinase
(MAPK) cascade contributing to the development of atheroscle-
rosis (Hou et al., 2000). However, adenosine derived from
the enzymatic breakdown of ATP by ecto-5′-nucleotidase (see
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Figure 1) acts as an endogenous modulator protecting against
vascular inflammation and immune cell recruitment, therefore,
preventing the progression of atherosclerosis (Buchheiser et al.,
2011). Adenosine in concert with A2A and A2B receptors has also
been shown to stimulate endothelial cell proliferation and regu-
late the release of platelet-derived growth factor (PDGF) a smooth
muscle mitogen from platelets (Jonzon et al., 1985; Adair, 2005).
Moreover, inflammationstimulatedbyaccumulationofox-LDL
in the atherosclerotic plaque activates the release of cytokines and
metalloproteinases resulting in degradation of the fibrous cap
(Erlinge and Burnstock, 2008). These events result in a weak
plaque, which can potentially rupture and release its content
into the circulation. This content is highly thrombogenic and
produces activation of platelets causing the formation of local
thrombus occluding the artery or embolising and resulting in
ischemic stroke or myocardial infarction (Erlinge and Burnstock,
2008) Pinheiro et al. demonstrated using human subcutaneous
fibroblast that the release of histamine induces an increase in
intracellular Ca2+ resulting in the release of ATP via Panx-1
hemichannels (Pinheiro et al., 2013). Furthermore, the release of
ATP activates P2 receptors and results in fibroblast proliferation
and collagen production. The principal cell type of vascular
adventitia is fibroblast therefore increase proliferation of this cell
type could contribute to atherosclerotic lesion progression and
eventual rupture. This evidence suggests a complex mechanism,
which results in plaque destabilization, and involves mast cells,
histamine,P2receptors,ATP,Panx-1hemichannelsandfibroblasts.
ROLE OF PANX-1 HEMICHANNELS IN APOPTOSIS
There are two main types of cell deaths, apoptosis and necrosis.
Morphological features such as cell rounding, DNA fragmenta-
tion, externalization of phosphatidyl serine, caspase activation
and the lack of an inflammatory reaction characterize apopto-
sis. Necrosis is characterized by swelling of organelles and plasma
membrane, followed by the collapse of the plasma membrane
and ending in the uncontrolled release of intracellular contents
after the membrane has ruptured which leads to an inflammatory
response. Intact apoptotic cells have been shown to release ATP
and UTP without extrusion of additional cellular contents, sug-
gesting the opening of relatively large membrane pores such as
Cxs or Panx hemichannels during the apoptotic process (Harris,
2007; Elliott et al., 2009; Ghiringhelli et al., 2009; Scemes et al.,
2009; MacVicar and Thompson, 2010).
Chekeni et al. showed in Jurkat cells that the channels involved
in the release of ATP and UTP in apoptotic cells were Panx
hemichannels and not Cxs hemichannels (Chekeni et al., 2010).
Inhibition of these channels using 18-alpha-glycyrrhetinic acid
(18AGA) or flufenamic acid (FFA), which are efficient Cxs
hemichannel blockers had no effect on, the release of ATP induced
by intact apoptotic cells (Chekeni et al., 2010). However, when
specific Panx hemichannel blockers were used such as probenecid,
the release of ATP was blocked from intact apoptotic cells. ATP is
a chemoattractant for immune cells thus blocking ATP release by
inhibiting Panx-1 hemichannel opening results in a decrease in
monocyte recruitment (Chekeni et al., 2010).
Overexpression of Panx-1 increases the release of nucleotides
during apoptosis, subsequently increasing monocyte migration.
Activation of caspases 3/7 results in opening of Panx-1 hemichan-
nels by a mechanism that involves cleavage of the Panx-1
intracellular carboxy terminal region increasing the release of ATP
and UTP which is vital for apoptosis. Using whole cell patch
clamp it was determined that opening of Panx-1 hemichannels
and subsequent release of ATP occurs in the early events of apop-
tosis, and no opening of Panx-1 hemichannels was observed in
the later events of apoptosis (Chekeni et al., 2010). Sandilos et al.
determined that the C-terminus functions as a dissociable chan-
nel blocker, capable of inhibiting C-terminally truncated Panx-1
hemichannels and relief of C-terminal inhibition followed by
cleavage does not happen if the C terminus is covalently tethered
to the channel pore (Sandilos et al., 2012). This evidence suggests
a role for Panx-1 hemichannels in the early events of apoptosis.
Divergent from the idea that Panx-1 hemichannels do not
form gap junctions Vanden Abeele et al. demonstrated that over-
expression of Panx-1 induces formation of Ca2+permeable gap
junction channels between cells allowing cellular Ca2+ diffu-
sion and facilitating intercellular Ca2+ wave propagation (Vanden
Abeele et al., 2006). Panx-1 overexpression also increased the
Ca2+ permeability of the endoplasmic reticulum (ER) membrane
and affected intraluminal ER Ca2+ concentration. Using human
prostate cancer epithelial cells (LNCaP) and human embryonic
kidney cells (HEK-293) they demonstrated that while overexpres-
sion drastically reduced intraluminal Ca2+, endogenous Panx-1
depletion using siRNA increased the content of Ca2+ in the ER.
This data suggests that Panx-1 hemichannels are not only found
on the plasma membrane but also in the ER membrane, and it
participates in ER Ca2+ leak and intracellular Ca2+movement.
Vanden Abeele et al speculated that the reduced concentration of
Ca2+ associated with Panx-1 overexpression could be caused by
increase of the BCL-2 family of proteins which plays an important
role in the regulation of calcium leak from the ER and is an anti-
apoptotic protein (Pinton et al., 2000; Vanden Abeele et al., 2002,
2006; Bassik et al., 2004). It may also be due to a deficiency of two
pro-apoptotic proteins Bax and Bak (Scorrano et al., 2003; Oakes
et al., 2005). This data suggests that Panx-1 could be involved in
apoptotic events taking place in endomembranous compartments
such as the ER.
PURINERGIC RECEPTORS AND PANX-1 HEMICHANNEL
IMPORTANCE IN HIV-1 INFECTION
The first clinical observations of acquired immune deficiency syn-
drome (AIDS) were reported in 1981. Since the identification of
HIV as the virus responsible for AIDS the countries affected and
the numbers of those infected rose to overwhelming numbers. As
of 2011, there are 34 million people worldwide living with HIV
according to the World Health Organization. A total of 2.5 mil-
lion new infections were reported in 2011 with 1.7 million deaths
related to AIDS.
The established model for HIV entry into cells is mediated by
the binding of HIV glycoprotein (gp) 120 to the cellular CD4
receptor. This interaction induces a conformational change to
allow the glycoprotein to bind to the co-receptors CXCR4 and/or
CCR5. The interaction of gp120 with these two host receptors
creates a stable attachment between the virus and the cell mem-
brane facilitating successful viral entry into the cell. In the past
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two decades studies have documented that binding of HIV or
gp120 to the cell rapidly increases the intracellular free calcium
concentration (Weissman et al., 1997; Arthos et al., 2000; Liu
et al., 2000; Balabanian et al., 2004; Melar et al., 2007). This
rapid increase of intracellular free calcium suggests the potential
involvement of other membrane receptors or channels in the early
stages of HIV infection.
Our laboratory demonstrated that HIV infection of periph-
eral blood mononuclear cells (PBMCs) and CD+4 T lymphocytes
causes opening of Panx-1 hemichannels in a biphasic man-
ner (Orellana et al., 2013). Binding of the virus to its receptor
(CD4) and co-receptors (CXCR4 and/or CCR5) induces open-
ing of Panx-1 hemichannels. Opening of Panx-1 hemichannels
in response to the virus resulted in ATP release and subsequent
purinergic receptor activation. We also showed that opening of
Panx-1 hemichannels was required for HIV entry and replica-
tion in CD+4 T lymphocytes. We propose that opening of Panx-1
hemichannels results in an increase of intracellular calcium and
subsequent actin rearrangement, which is a necessary step that
allows the virus to fuse with the host cell membrane. The details
of these mechanisms are currently under investigation.
Our laboratory recently described a novel role for purinergic
receptors in HIV replication in macrophages (Figure 2). We iden-
tified that P2X1, P2X7, and P2Y1 participate in HIV replication.
Demonstrating that P2X1 is key in controlling viral entry into
human macrophages. Although P2X7 and P2Y1 did not inhibit
entry, it is highly likely that these receptors participate in later
stages of the viral life cycles (Hazleton et al., 2012). We also
identified the gp120’s binding to primary human macrophages
induces the release of ATP which facilitates autocrine activation
of purinergic receptors. Panx-1 hemichannels, purinergic recep-
tors and extracellular ATP play a key role in HIV infection and
replication of HIV in immune cells by contributing to entry
and possibly in other steps of the viral life cycle. In agreement
another study using cell lines and PBMCs indicates that extra-
cellular ATP activates P2Y2 receptors resulting in Pyk2 Kinase
activation (Seror et al., 2011). It has been reported that Panx-
1 hemichannels, P2Y2 and Pyk2 are physically recruited to the
infection synapse (the contact site between the viral and cellular
membrane) in order to facilitate infection (Seror et al., 2011). We
propose that this process causes membrane depolarization and
assists in membrane-to-membrane fusion allowing viral entry.
POTENTIAL HEMICHANNEL AND PURINERGIC RECEPTOR
THERAPIES
Purinergic receptor, Panx-1 hemichannel, and extracellular ATP,
ADP, AMP, and adenosine blockers and their potential use as
therapeutic agents are under current investigation. Commercially
FIGURE 2 | Proposed model for the role of Panx-1 hemichannels and
purinergic receptors in HIV infection. HIV’s binding to CD4 and
CXCR4/CCR5 (1) induces signaling which leads to opening of Panx-1
hemichannels and release of ATP (2). Extracellular ATP released through
open Panx-1 hemichannels binds to and activates P2X1 receptors
causing calcium influx (3), which facilitates HIV entry (4). The release of
ATP continues and activates P2X7 and P2Y1 receptors (5), causing
further calcium influx inducing downstream signaling, which facilitates
later stages of the HIV life cycle (8). Ecto-nucleoside triphosphate
diphosphydrolase (E-NTDPase) converts ATP to ADP (6), which activates
P2Y1 receptors (7), which increases intracellular calcium, which causes
signaling that facilitates later stages of the HIV life cycle (8).
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available pharmaceutical adenosine, such as adenocard and
adenoscan, are currently used to treat supraventricular tachy-
cardia, is an example of an ion channel targeted treatment
(Delacrétaz, 2006; Jacobson and Gao, 2006). Other clinically
used drugs include dipyridamole and methotrexate, which are
used to alter the extracellular adenosine concentration as well
as signaling. Currently the US Food and Drug Administration
(FDA) approved the A2A receptor agonist regadenoson (Lexiscan;
Astellas Pharma) for myocardial perfusion imaging in patients
with suspected coronary artery disease (Ghimire et al., 2013).
Among purinergic receptor blockers, which are, consumed
daily are food dyes such as Brilliant Blue G (BBG) and Brilliant
Blue FCF (BB FCF) which are found in most soft drinks. These
dyes are shown to block at least P2X7 receptors, and Panx-
1 hemichannels respectively (Jiang et al., 2000; Wang et al.,
2013). In addition millions of people worldwide consume caf-
feine, which antagonize adenosine receptors and is used to treat
premature apnoea. Actually, nothing is known of the effect that
these dyes and caffeine have in physiological and pathological
conditions. For example daily ingestion of these compounds in
HIV positive individuals could cause the virus to adapt to these
blockers changing the course of the disease. As mentioned above
these channels/receptors play a role in inflammation and immune
response, therefore individuals who consume these dyes in large
quantities could also suffer from a suppressed immune response
leading to numerous pathologies and susceptibility to pathogens.
Further studies are required to investigate the effect that these
dyes have among the human population.
The P2Y12 platelet receptor plays an important role in the gen-
esis of platelet aggregation (Power et al., 2012; Tam et al., 2012).
Current treatments blocking adenosine diphosphate (ADP) bind-
ing to the P2Y12 receptor, which inhibits platelet aggregation, are
commercially available as well as in clinical trials. The first gener-
ation thienopyridine drugs which are used for their anti-platelet
activity was ticlopidine, which bound irreversibly to P2Y12
platelet receptor (Cattaneo, 2010;Mohelmani and Jackson, 2012).
However, its toxicity led to the development of second-generation
thienopyridine clopidogrel (Ji and Hou, 2011). Clopidogrel also
has its limitations, such as a delay in platelet block because the
prodrug requires activation in the liver, and clopidogrel therapy
is irreversible which can lead to increase bleeding and transfu-
sion risk in cardiothoracic surgery (Power et al., 2012; Tam et al.,
2012). Third generation thienopyridine prasugrel addressed the
issue of delayed platelet blocking by being relatively indepen-
dent of hepatic activation, however, it still remained irreversible
and patients were still at risk for increase bleeding (Ferraris
et al., 2012). Ticagrelor is an orally administered direct acting
platelet blocker, which binds reversibly to the P2Y12receptor.
This drug does not require metabolic conversion. It also belongs
to a new class of drugs called cyclopyrimidines, which bind,
non-competitively to the P2Y12receptor independently of the
ADP binding site (van Giezen and Humphries, 2005). Ticagrelor
when compared to prasugrel has demonstrated a more promising
outcome with fewer side effects.
Numerous clinical trials are on going using various adenosine
receptor agonist and antagonist. The expectation are high and
could provide treatments for many physiological and pathological
conditions such as lipolysis, renal blood flow, immune function,
sleep regulation, angiogenesis, inflammatory diseases, ischemia-
reperfusion, and neurodegenerative disorders (Sun et al., 2001;
Huang et al., 2005; Fredholm, 2007; Johansson et al., 2007; Haskó
et al., 2008; Rosenberger et al., 2009; Liu et al., 2010; Eltzschig
and Carmeliet, 2011; Eltzschig and Eckle, 2011; Lazarus et al.,
2011; Grenz et al., 2012). However, developing adenosine receptor
targets is challenging because adenosine signaling is widespread.
Therefore it is necessary to use ligands, which could be success-
fully administered to affect the area of interest, while being safe to
use in a clinical setting.
Probenecid is a Panx-1 inhibitor, and has been on the mar-
ket for decades as a treatment for gouty arthritis. High levels
of extracellular potassium ion induce inflammasome activation
and caspase 1 cleavage in neurons and astrocytes. In addition
probenecid has been shown to attenuate the caspase 1 cleav-
age in cultured neurons induced by extracellular potassium ions
(Peng et al., 2009). Recent evidence using a mouse model has
shown that administering probenecid prior to and after stroke
induced reduced infarct size, decreased cerebral water content,
inhibited neuronal death, and reduced inflammation in the brain
(Xiong et al., 2014). These results suggest that probenecid could
be used as a treatment for stroke. Another Panx-1 inhibitor is
carbenoxolone prescribed to treat oesophageal ulceration and
inflammation. Probenecid and carbenoxolone could be ideal can-
didates as a treatment for pathological as well as physiological
conditions were the inhibition of Panx-1 hemichannels could be
useful. Other possible treatments could involve the use of mimetic
peptides, which are designed with sequences found in the two
extracellular loops of the Panx protein. These peptides mimic the
loop-to-loop interaction between two hemichannels and activate
a docking gate keeping the hemichannel closed. The designs of
better and more specific blockers are required in the treatment of
diseases involving Panx-1 hemichannels, purinergic receptors and
ATP/adenosine.
CONCLUSION
In this review we have discussed the role which purinergic recep-
tors and Panx-1 hemichannels play in the pathogenesis of several
human diseases. It is crucial to understand the contribution of
these receptors and channels in physiological and pathological
conditions, in order to design new and improved therapeutic
approaches. The contribution that purinergic receptors and Panx-
1 hemichannels play in the HIV viral life cycle has only been
recently described and unlocking this relationship could hold
the key to the development of new preventative therapies and
treatments. Purinergic receptor, Panx-1 hemichannel, and extra-
cellular ATP, ADP, AMP, and adenosine are important modulators
of many cellular events and hold great potential in understanding
and treating many pathological and physiological conditions. The
pathologies discussed in this review contribute to a large number
of fatalities worldwide. Although much progress has been made
in the advancement of treatments for these pathologies, there are
still many avenues, which have not been explored. As more infor-
mation regarding Panx-1 hemichannels and purinergic receptors
emerge, the possibility of new therapeutic opportunities for these
pathologies emerges as well.
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